Reevaluation of the treatment of shock secondary to cardiac infarction.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000818:Animals; D001783:Blood Flow Velocity; D001794:Blood Pressure / Q000187:drug effects; D001810:Blood Volume / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D003331:Coronary Vessels / Q000187:drug effects; D004071:Digitalis Glycosides / Q000627:therapeutic use; D004285:Dogs; D004298:Dopamine / Q000627:therapeutic use; D004562:Electrocardiography; D005112:Extracorporeal Circulation; D005934:Glucagon / Q000627:therapeutic use; D006439:Hemodynamics; D007545:Isoproterenol / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000150:complications* / Q000188:drug therapy; D009638:Norepinephrine / Q000494:pharmacology; D010643:Phenoxybenzamine / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use; D012769:Shock / Q000188:drug therapy* / Q000209:etiology; D014655:Vascular Resistance / Q000187:drug effects
D000305:Adrenal Cortex Hormones; D004071:Digitalis Glycosides; D010643:Phenoxybenzamine; D005934:Glucagon; D011433:Propranolol; D007545:Isoproterenol; D004298:Dopamine; D009638:Norepinephrine